The content on this site is intended for healthcare professionals only
Dr Donald Bastin talks to ecancer about real-world findings from the Canadian CASCADE database evaluating tarlatamab in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC).
This interim analysis included 35 patients treated after at least two prior lines of therapy, many with brain or liver metastases. At a median follow-up of 8.2 months, real-world overall survival was 72% at three months and 57% at six months, with a median real-world progression-free survival of 2.5 months.
Dr Bastin discusses the effectiveness and safety findings, including cytokine release syndrome (CRS) in 68% of patients and immune effector cell-associated neurotoxicity syndrome (ICANS) in 17%.
The results offer insight into tarlatamab use in routine clinical practice, highlighting both its potential clinical activity and the need to interpret outcomes cautiously given the small cohort and limited follow-up.
Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC
Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC
Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification
The potential of T-cell engagers in SCLC treatment
Making immune check point inhibitors for lung cancer cost-effective in LMICs
ASCO 2025: Latest in EGFR positive NSCLC
Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC
